Advertisements

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab.....»»

Category: press-releasesSource: businesswireindiaJan 11th, 2017

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Pegfilgrastim for Review

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Pegfilgrastim for Review.....»»

Category: press-releasesSource: businesswireindiaFeb 16th, 2017

EMA accepts Biocon, Mylan biosimilar for review

EMA accepts Biocon, Mylan biosimilar for review.....»»

Category: topSource: the-hinduAug 25th, 2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Mylan-Biocon seek USFDA nod for biosimilar version of cancer drug

Mylan-Biocon seek USFDA nod for biosimilar version of cancer drug.....»»

Category: featuresSource: livemintNov 9th, 2016

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab.....»»

Category: press-releasesSource: businesswireindiaNov 8th, 2016

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab.....»»

Category: press-releasesSource: businesswireindiaNov 8th, 2016

Trastuzumab marketing approval may come in 12-18 months: Biocon

Trastuzumab marketing approval may come in 12-18 months: Biocon.....»»

Category: topSource: moneycontrolAug 26th, 2016

EMA accepts Mylan, Biocon Trastuzumab biosimilar for review

EMA accepts Mylan, Biocon Trastuzumab biosimilar for review.....»»

Category: topSource: moneycontrolAug 25th, 2016

Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency

Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency.....»»

Category: press-releasesSource: businesswireindiaAug 25th, 2016

Mylan, Biocon report efficacy of cancer drug

Mylan, Biocon report efficacy of cancer drug.....»»

Category: topSource: the-hinduJun 5th, 2016

Mylan, Biocon confirm efficacy of trastuzumab biosimilar

Mylan, Biocon confirm efficacy of trastuzumab biosimilar.....»»

Category: topSource: moneycontrolJun 4th, 2016

EMA accepts Biocon, Mylan insulin for review

EMA accepts Biocon, Mylan insulin for review.....»»

Category: topSource: the-hinduNov 3rd, 2016

European regulator EMA to review Biocon-Mylan cancer drug - Livemint

European regulator EMA to review Biocon-Mylan cancer drug - Livemint.....»»

Category: topSource: googlenewsAug 25th, 2016

Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency

Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency.....»»

Category: press-releasesSource: businesswireindiaJul 21st, 2016

Mylan, Biocon confirm efficacy of trastuzumab biosimilar

Mylan, Biocon confirm efficacy of trastuzumab biosimilar.....»»

Category: featuresSource: business-standardJun 4th, 2016

Mylan, Biocon confirm efficacy of trastuzumab biosimilar

Mylan, Biocon confirm efficacy of trastuzumab biosimilar.....»»

Category: featuresSource: livemintJun 4th, 2016

Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting

Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting.....»»

Category: press-releasesSource: businesswireindiaJun 3rd, 2016